Picture of Frontage Holdings logo

1521 — Frontage Holdings News Story

0.000.00%
hk flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall Cap

Hong Kong's Frontage Holdings H1 profit more than doubles on Teddy Lab acquisition

Hong Kong's Frontage Holdings H1 profit more than doubles on Teddy Lab acquisition


Overview

  • Hong Kong-based CRO's H1 revenue rose 17% yr/yr to $148.2 mln

  • Net profit for H1 more than doubled to $6.8 mln

  • Company completed Teddy Lab acquisition, expanding laboratory capabilities in China


Outlook

  • Company did not provide specific financial guidance for the current quarter or full year


Result Drivers

  • TEDDY LAB ACQUISITION - Co said acquisition of Teddy Lab in China expanded laboratory capabilities and contributed to growth

  • LABORATORY-TESTING DEMAND – North America and Europe revenue rose 7.8%, driven by laboratory-testing demand, higher capacity use and marketing efforts

  • TECHNOLOGY INVESTMENT - Co said continued investment in AI-assisted workflows and laboratory automation improved efficiency and turnaround time

  • STRONG CONTRACT PIPELINE - Co reported contract future revenue rose 34% yr/yr to $543.2 mln, indicating robust demand for services


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Revenue

$148.20 mln

H1 Net Profit

$6.80 mln


Analyst Coverage

  • The current average analyst rating on the shares is "sell" and the breakdown of recommendations is no "strong buy" or "buy", no "hold" and 2 "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy."

  • Wall Street's median 12-month price target for Frontage Holdings Corp is HK$0.97, about 19.2% below its August 28 closing price of HK$1.20

  • The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 25 three months ago


Reuters Recommended Reads

  • Aug 28 - China's Tigermed Consulting H1 revenue rises amid clinical demand recovery

  • Aug 25 - WuXi Biologics H1 net profit up on margin expansion

  • Aug 25 - McKesson strikes $2.25 billion Precision Medicine deal in clinical research bets


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Frontage Holdings

See all news